SUMMARY The electrophysiological effects of flecainide acetate (2 mg/kg as an intravenous infusion over five minutes) were assessed in 47 patients undergoing electrophysiological study. Seven patients had normal electrophysiology, 16 had a direct accessory atrioventricular pathway, 12 had dual atrioventricular nodal (AH) pathways, five had paroxysmal ventricular tachycardia, six had conduction system disease, and one patient had a left atrial tachycardia.
Flecainide acetate4 (N-(2-piperidylmethyl)-2,5-bis (2,2,2-trifluoroethoxy) benzaamide acetate) belongs to a unique series of trifluoroethoxybenzamides' 2 which have proven antiarrhythmic activity against a variety of experimentally induced arrhythmias. [3] [4] [5] Human pharmacokinetic studies have shown that flecainide is almost completely absorbed after oral administration, undergoes minimal hepatic biotransformation, and has a long plasma elimination half-life ranging from 11 to 22 hours,67 properties that are highly desirable for the long term use of antiarrhythmic agents.
This study was undertaken to investigate the acute electrophysiological effects of intravenous flecainide on cardiac conduction and refractoriness in man.
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Accepted for publication 11 March 1982 Patients and methods Forty-seven patients, 27 male and 20 female, whose ages ranged from 16 to 80 (mean 42) years, underwent routine electrophysiological study for the investigation of either symptoms suggesting or documentary evidence of recurrent arrhythmias or cardiac conduction disturbances. The majority of patients with episodes of documented tachycardia had been previously treated with a variety of antiarrhythmic agents.
The clinical data are summansed in Table 1 .
Seven patients, in whom arrhythmias could not be provoked, were found to have normal cardiac electrophysiology. Sixteen patients had an accessory atrioventricular pathway with atrioventricular reentrant (orthodromic) tachycardia which could be provoked. In eight of these patients accessory pathway conduction was bidirectional with ventricular pre-excitation (Wolff-Parkinson-White syndrome) while the other eight had conduction in the retrograde ventriculoatrial direction alone (that is electrophysiologically concealed). Twelve patients had Cardiac electrophysiology offlecainide tDigiirmer Ltd, Welwyn, Hertfordshire, England "programmable" stimulator using pulse amplitudes at twice diastolic threshold9 and pulse durations between 15 and 2-5 ms. Conduction intervals were studied during sinus rhythm and during constant rate atrial pacing slightly above sinus rate. Anterograde and retrograde conduction characteristics and refractoriness of the heart were determined by the introduction of an extrastimulus after regular atrial or ventricular pacing at a cycle length of 600 ms in most instances. 9 10 Incremental atrial pacing from the high right atrium was performed until atrioventricular Wenckebach periodicity occurred or a minimum pacing [12] [13] [14] Hellestrand, Bexton, Nathan, Spurrell, Camm Intraventricular conduction was measured as the QRS duration from the earliest onset of ventricular activation to the latest J point of the QRS complex in any surface electrocardiographic lead. The QT interval was measured from the earliest onset of ventricular activation to the point at which the latest T wave returned to the isoelectric line. The JT interval during identical rate atrial pacing was used as an index of ventricular repolarisation and was measured from the J point to the point at which the latest T wave returned to the isoelectric line, that is JT=QT-QRS.
Atrioventricular Wenckebach cycle length was defined as the longest atrial cycle length at which anterograde Wenckebach periodicity occurred during incremental atrial pacing. 12-14 Ventriculoatrial Wenckebach cycle length was defined as the longest ventricular cycle length at which retrograde Wenckebach periodicity occurred during incremental ventricular pacing. 9 Effective refractory period of the atrium was defined as the longest coupling interval of an atrial premature stimulus which failed to cause atrial depolarisation. Effective refractory period of the atrioventricular node was defined as the longest coupling interval of an atrial premature stimulus which failed to cause His bundle depolarisation. Ventricular effective refractory period was defined as the longest coupling interval of a ventricular premature stimulus which failed to cause ventricular depolarisation. 9 An atrioventricular accessory pathway was defined as a direct atrioventricular connection which bypassed normal atrioventricular nodal and His-Purkinje conduction.'5 Anterograde effective refractory period of an accessory pathway was defined as the longest coupling interval of an atrial premature beat at which block occurred in the accessory pathway with normalisation of the atrial to ventricular activation sequence or at which the atrial premature stimulus failed to conduct to the ventricles. Retrograde effective refractory period of an accessory pathway was defined as the longest coupling interval of a ventricular premature beat at which block occurred in the accessory pathway with normalisation of the retrograde ventricular to atrial activation sequence or at which the ventricular premature stimulus failed to conduct to the atria.
An atrioventricular nodal "fast" pathway was defined as a path which showed the electrophysiological properties of fast, non-decremental conduction and a relatively long refractory period.16-18 Anterograde effective refractory period of an atrioventricular nodal "fast" pathway was defined as the longest coupling interval of an atrial premature beat at which block in the "fast" pathway occurred with a sudden increase and normalisation of the AH conduction time or at which the atrial extrastimulus failed to conduct to the His bundle and ventricles.'718 Retrograde effective refractory period of an atrioventricular nodal "fast" pathway was defined as the longest coupling interval of a ventricular premature beat at which a sudden increase in the retrograde V to A conduction time occurred or at which the ventricular extrastimulus failed to conduct to the atria.
An atrioventricular nodal "slow" pathway was defined as a path demonstrating the electrophysiological properties of slow, decremental conduction with a relatively short effective refractory period. [16] [17] [18] Anterograde effective refractory period of an atrioventricular nodal "slow" pathway was defined as the longest coupling interval of an atrial premature beat at which the atrial extrastimulus failed to conduct to the His bundle,'7 18 when anterograde conduction block had previously occurred in the "fast" pathway at longer atrial extrastimulus coupling intervals. Retrograde effective refractory period of an atrioventricular nodal "slow" pathway was defined as the longest coupling interval of a ventricular premature beat at which the ventricular extrastimulus failed to conduct to the atria when retrograde conduction block had previously occurred in the "fast" pathway at longer ventricular extrastimulus coupling intervals.
Accessory pathway and dual AH pathway refractory periods were measured from the same intracavitary positions as close to the pathway as possible before and after drug administration.
STATISTICS
Statistical data were analysed using Student's t test for paired data.
Results
Comparative electrophysiological data are summarised in Tables 2 and 3 . All measurements are written as the mean value + one standard deviation from the mean.
CONDUCTION (TABLE 2) Flecainide produced a small insignificant decrease in sinus cycle lengths from 745+198 to 734±180 ms. The PA interval prolonged significantly from 41 ± 13 to 50± 13 ms; p<0001. AH conduction times during sinus rhythm, excluding two patients with overt ventricular pre-excitation which obscured the His potential and the patient with left atrial tachycardia, prolonged from 67+21 to 81+33 ms; p<0-001. Similar AH prolongation occurred during constant rate atrial pacing slightly faster than sinus rates (84±_33 to 101+ 39 ms; p<0 001). Flecainide produced complete AH block in one patient with intermittent Wenckebach second degree AV block present before drug administration.
Cardiac electrophysiology offiecainide His-Purkinje conduction times measured in the 39 patients without overt ventricular pre-excitation prolonged considerably from 44±9 to 61 + 12 ms; p<0*001 ( (Fig. 2) . QRS durations increased in 44 patients and remained unchanged in three patients. The maximum QRS prolongation was 75 ms in a patient who developed complete right bundle-branch block after flecainide administration. The increment in QRS duration expressed as a percentage of the control QRS duration ranged from 0 to 79%, with a mean of 23%.
QT intervals were compared in the 39 patients without ventricular pre-excitation. The QT intervals during sinus rhythm (368±43 to 382+44 ms; p<0-02), constant rate atrial pacing (342+25 to 349±30 ms; p<0.01), and the corrected QT interval derived from Bazett's formula (Q-Tc=Q-T measured! (R-R interval in s)05) showed slight significant lengthening (427+34 to 446±40 ms; p<0-001). The JT interval shortened slightly from 246±27 to 232±+33 ms; p<0*001. Fig. 3 from 300+49 to 453+169 ms (p<001). Complete retrograde accessory pathway block occurred in seven patients, all of whom had concealed conduction. Ventricular effective refractory periods in these 16 patients changed slightly from 215 ±22 to 227±24 ms (p<O-01).
(v) Dual AH pathways Anterograde atrioventricular "fast" pathway refractoriness was not significantly affected (342+59 to 364+59 ms). One patient developed complete block in the anterograde "fast" pathway. Retrograde ventriculoatrial "fast" pathway refractoriness prolonged considerably from 315±99 to 450±144 ms (p<0.01).
Five out of 12 "fast" pathways showed complete retrograde block after flecainide administration. No significant changes in refractoriness of the atrioventricular nodal "slow" pathways were observed in either the anterograde or retrograde direction. The majority of "slow" pathway values were, however, limited by atrial refractoriness.
SERUM LEVELS OF FLECAINIDE
Blood for flecainide levels, collected 15 to 30 minutes after drug administration, disclosed serum flecainide levels ranging from 85 to 785 (mean 335) ng/ml. Serum levels of flecainide did not correlate with acute changes observed in conduction intervals or refractory periods.
SIDE EFFECTS
One patient experienced a significant arrhythmia after flecainide administration. This patient, with ventricular pre-excitation, developed ventricular flutter during ventricular extrastimulation after but not before flecainide had been given. Complete AH block occurred in one patient with prior Wenckebach second degree atrioventricular block, and one patient with underlying bifascicular block (right bundle branch block and left anterior hemiblock) developed complete HV block during drug administration. Because of slow ventricular escape rhythms both of these patients required ventricular pacing for periods of 20 to 30 minutes until atrioventricular conduction returned. Minor side effects that occurred only during drug administration included oral paraesthesiae in over 90% of patients and transient drowsiness and dizziness in a small minority. Several patients complained of slight local pain at the site of injection.
Discussion
After initial reports describing the synthesis and antiarrhythmic potential of a series of N-(aminoalkyl) trifluoroethoxybenzamides, one of these compounds, flecainide acetate (R818), has been studied extensively using animal models. ' 2 Its antiarrhythmic potency in dogs, pigs, and mice compared very favourably with reference compounds quinidine, procainamide, and lignocaine when used both parenterally and orally against a variety of experimentally induced supraventricular and ventricular arrhythmias. [3] [4] [5] An evaluation of the intracellular electrophysiological effects of flecainide using isolated rabbit atria showed slowing of conduction velocity and a striking reduction in the maximum rate of depolarisation of the action potential. The effect of flecainide on repolarisation was to produce an alteration in the shape of the action potential without prolonging its duration. Flecainide reduced the spontaneous frequency of sinus node discharge and had a small negative inotropic effect on isolated rabbit atrial muscle. 19 All of the properties manifested by flecainide are typical of Vaughan Williams Class 1 agents20 and imply that this drug restricts the fast inward movement of sodium ions. ' Further human electrophysiological studies combining right ventricular monophasic action potential recordings with programmed ventricular stimulation using larger intravenous doses of flecainide showed significant prolongation of the ventricular effective refractory period concomitant with prolongation of ventricular repolarisation. 22 The electrophysiological results of the present series show that flecainide significantly depresses conduction within working myocardium and throughout the specialised conduction system. Right atrial conduction was significantly delayed. Ventricular conduction measured by the QRS duration was severely depressed as described by Orning2l and Olsson and Edvardsson22 in their initial studies. Atrioventricular nodal conduction times, independent of any raterelated changes in the AH interval, were prolonged by flecainide. The most pronounced effect appeared to be on His-Purkinje conduction where the HV interval prolonged beyond the normal range9 in 70% of patients after flecainide administration and transient complete HV block occurred in one patient. These changes in cardiac conduction caused by flecainide could be reliably produced in'the His-Purkinje system and ventricle but were Hellestrand, Bexton, Nathan, Spurrell, Camm
The concept of the JT interval was introduced as another index of ventricular repolarisation in order to exclude errors resulting from drug-induced prolongation of ventricular depolarisation. The JT interval did not prolong after flecainide administration which suggests that this drug, unlike quinidine (a Vaughan Williams class la drug) or lignocaine (a Vaughan Williams class lb drug), does not materially affect ventricular repolarisation.
The electrophysiological properties of flecainide do not fall strictly within the modified criteria used to define Vaughan Williams class la and class lb agents.24 D C Harrison (1981, personal communication) has proposed that a further subgroup, class lc, should be used to define such drugs including encainide25 and lorcainide,26 both of which manifest many electrophysiological similarities to flecainide.
Touboul et al. 27 have recently suggested a classification of antiarrhythmic agents according to their electrophysiological characteristics defined by standard electrophysiological assessment. According to this proposed classification flecainide manifests class 3 antiarrhythmic activity, which comprises drugs showing a wide electrophysiological spectrum. In addition to atrioventricular nodal depression they prolong HV conduction times (aprindine28 29) or His-Purkinje refractoriness (amiodarone29 30). These class 3 drugs may also lengthen refractoriness of accessory pathways and atrial myocardium.
A most profound effect on accessory atrioventricular pathways and "fast" nodal pathways was produced by flecainide. After intravenous administration of the drug complete anterograde block occurred in two out of eight overt accessory atrioventricular pathways and complete retrograde block occurred in seven of 16 accessory atrioventricular pathways. Of the six remaining overt accessory pathways, anterograde refractoriness increased in all cases. Of the nine accessory pathways still capable of retrograde conduction after flecainide administration, refractoriness increased in four patients and in two cases accessory pathway refractoriness slightly shortened. In three cases assessment of accessory pathways refractoriness was limited by ventricular refractoriness.
In the 16 patients with accessory atrioventricular pathways it is of interest that flecainide has such a significant depressant effect on accessory pathway refractoriness compared with the changes in atrial or ventricular myocardial refractoriness in the same patients. These findings suggest that bypass tracts possess electrophysiological characteristics quite distinct from those of atrial or ventricular muscle.
In the 12 patients with dual AH pathways flecainide acetate selectively affected "fast" atrioventricular nodal pathway refractoriness, specifically retrograde refractoriness of this "fast" pathway. Complete
